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 ABSTRACT 
 
 
ANAAM F. MOHAMMED 
Assessment of Rotavirus Vaccine Type and Number of Doses on Severity of Disease 
(Under the direction of Dr. Lisa Casanova, Faculty Member) 
 
 
Background: Rotavirus disease is the leading global cause of severe diarrhea in children under 5 
years. We examined the association between different rotavirus vaccines doses and severity of 
diarrhea.  
 
Methods: A secondary analysis of surveillance of children with acute gastroenteritis (AGE) 
symptoms during two seasons (January-June) in 2010 and 2011 from three pediatric hospitals in 
Atlanta, Georgia was conducted. Enrolled children were tested for rotavirus, using EIA 
(Rotaclone) and vaccination records were collected from the state immunization registry and 
healthcare providers. Cases were defined as any enrolled child who tested positive for rotavirus. 
Each enrolled child was assigned a Vesikari score to assess AGE severity.  
 
Results: 63.9% of participants had severe AGE. Cases were more likely to have severe AGE 
than controls (OR 3.8, 95% CI: 2.2-6.5). Receiving a mixed vaccine regimen had similar 
protection against severe disease to receiving only RotaTeq® or Rotarix® (Mixed: OR 0.1, 95% 
CI: 0.02-0.5; RotaTeq®: OR 0.1, 95% CI: 0.02-0.5; Rotarix®: OR 0.1; 95% CI 0.01-0.3). When 
controlling for vaccine type and demographic covariates, three doses of vaccine offered 
significant protection against severe disease (OR 0.3, 95% CI: 0.2-0.6). 
Conclusions: Receiving a mixed regimen of rotavirus vaccine is effective in preventing severe 
AGE. Mixed rotavirus vaccine regimens were equally efficacious to receiving a single type of 
vaccine in preventing severe disease. Three doses of vaccine, regardless of type, were effective 
in preventing severe disease but one or two doses were not.  
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CHAPTER I: 
INTRODUCTION 
 
1.1 Background  
Rotavirus remains the leading cause of severe diarrhea in children under the age of five 
worldwide. In 2008, rotavirus was responsible for 453,000 deaths among children younger than 
five.
20
 Rotavirus is the most common organism which causes gastroenteritis in children. Deaths 
due to rotavirus overwhelmingly occur in developing countries, with approximately 85% of all 
rotavirus deaths occur in Africa and Asia. The World Health Organization estimates that 
rotavirus diarrhea results in approximately half a million deaths and approximately 2.4 million 
hospitalizations in developing countries each year.
2 
There are currently two widely used rotavirus vaccines: Rotarix® (GlaxoSmithKline 
Biologicals), a human, live attenuated 2-dose vaccine and RotaTeq® (Merck), a live, oral 
pentavalent 3-dosevaccine.
2
 Rotavirus vaccines have been included in the regular immunization 
schedule for children in the US since 2006. Efficacy of RotaTeq® and Rotarix® ranges from 
39% to 77% in developing countries, such as those in Africa and Asia.
3
 Several studies 
conducted in the United States have reported considerable reduction in illness caused by 
rotavirus after the introduction of rotavirus vaccines. Similarly, a greater number of rotavirus 
vaccine doses have been associated with reduction in disease complications.
8 In developed 
countries, rotavirus vaccines have demonstrated high efficacy against severe rotavirus disease 
(pooled efficacy =85%).
9
 A recent study of the effectiveness of both rotavirus vaccines in Spain 
revealed no significant differences between RotaTeq® and Rotarix®.
10
 The efficacy of mixed 
doses has not been previously assessed.  
1.2 Purpose of Study 
To determine the effect of receiving Rotarix®, RotaTeq®, or a mixed dose of the 
vaccines on the severity of rotavirus disease, this secondary analysis of a case-control study of 
participants from Children’s Healthcare of Atlanta hospitals was undertaken. The purpose of this 
study was to examine the association between the type and number of doses of rotavirus vaccine 
and the severity of disease in children under three.  
1.3 Research Questions 
1. Does the type of rotavirus vaccine children receive (RotaTeq® vs. Rotarix® vs. mixed) 
affect the severity of their disease as measured by the Vesikari scale? 
2. Does the number of doses of rotavirus vaccine children receive affect the severity of their 
disease as measured by the Vesikari scale? 
  
CHAPTER II: 
LITERATURE REVIEW 
 
2.1 Burden of Rotavirus Disease 
Rotavirus is the leading cause of severe diarrhea in children under the age of five 
worldwide. By the age of five, nearly every child in the world has been infected with rotavirus at 
least once.
1
 Deaths due to rotavirus occur disproportionately in developing countries, with 
approximately 85% of all rotavirus deaths occurring in Africa and Asia.
2
 Prior to the introduction 
of the rotavirus vaccines, over 40% of pediatric hospital admissions for diarrhea worldwide were 
caused by rotavirus infections.
10
  
Similarly, United States hospital discharge database, the Healthcare Cost and Utilization 
Project (HCUP) data was used to extrapolate that rotavirus was the cause of ~60,000 
hospitalizations and 37 deaths in the US annually.
16
 Before the introduction of rotavirus vaccines 
in the US, 410,000 doctor’s visits, 70,000 hospitalizations, and 272,000 Emergency Department 
(ED) visits were attributed to rotavirus annually. This burden represented a societal cost of close 
to $1 billion.
23
  
In 2007, rotavirus diarrhea was associated with an estimated annual healthcare cost of 
$319 million and a total annual cost to society of $893 million.
17
 The rotavirus gastroenteritis-
associated hospitalization burden is substantial, both in terms of the number of hospital visits and 
the cost.
18
 
2.2 Disparities in Rotavirus Disease in the United States 
Although national introduction of both RotaTeq® and Rotarix® has caused an overall 
decline in rotavirus gastroenteritis hospitalizations in children of all races, the same disparities in 
rotavirus disease observed in pre-vaccine years persist in the US. Particularly, race and insurance 
status account for some of the disparities.
16-18
 For example, the Medicaid population had a 
disproportionate number of hospitalizations from rotavirus gastroenteritis than non-Medicaid 
populations.
18
  
 Adjusting for age, Black children were found to have a lower visit rate for diarrhea 
associated illness than White children in outpatient setting but a higher visit rate for diarrhea-
associated illness in the ED setting. Conversely, Whites had a significantly greater (40%) rate of 
healthcare utilization for diarrhea-associated illness outpatient clinics than Blacks, but Blacks 
utilized the ED for diarrhea-associated illness at nearly double the rate of Whites. These data 
suggest that race may influence site of care for diarrhea-associated illness in children.
17
 
Similarly, data from HCUP found that Black infants had a significantly higher risk of being 
hospitalized and dying from rotavirus early in life, when compared to Whites.
16 
2.3 History of Rotavirus Vaccines 
The first rotavirus vaccine was introduced in 1998. RotaShield® (Wyeth) was a 
tetravalent vaccine that contained the G1-G4 rotavirus strains. After clinical trials that proved it 
to be 80-100% effective in preventing severe diarrhea, RotaShield® was licensed for use in the 
US. However, it was later discovered to have possibly contributed to an increased risk for 
intussusception in one in every 12,000 vaccinated infants, and was therefore, removed from the 
market in 1999.
20
  
In 2006, two new rotavirus vaccines were introduced: RotaTeq® and Rotarix®.
2,10
 In the 
US, the rotavirus vaccines were first recommended for all children in February 2006. Three years 
later, the World Health Organization Strategic Advisory Group of Experts recommended the 
rotavirus vaccine for all children. As of 2011, Rotarix® had been introduced into 27 national 
vaccine programs, and RotaTeq® had been introduced into 7national vaccine programs. Some 
countries, such as the US and Australia offer both vaccines, whereas others have switched from 
RotaTeq® to Rotarix® or vice versa or have still not introduced the vaccines.
7,10
 It is estimated 
that introduction of rotavirus vaccines in low-income countries would prevent 45% of deaths and 
approximately 58% of associated medical visits and costs due to rotavirus.
24 
Tracking intussusception rates before (2000-2005) and after (2007-2009) the introduction 
of RotaTeq® and Rotarix®, Yen and colleagues found a small increase in intussusception rates 
have been seen among infants aged 8-11 weeks with the first dose of the current rotavirus 
vaccines. Despite this, no population level changes in rates of intussusception hospitalizations 
have been noted.
15
  
In March 2010, porcine circovirus-1 (PCV-1) was identified in the Rotarix® vaccine. 
PCV-1 infects pigs but is not known to cause infections in humans. Still, the US Food and Drug 
Administration suspended use of Rotarix®. Further testing of both rotavirus vaccines revealed 
that RotaTeq® contained small amounts of PCV-1 and PCV-2, another porcine circovirus strain. 
The Rotarix® ban was removed by the FDA later in 2010 because the PCV strains pose only a 
theoretical risk to humans, as there has been no documented human infection by PCV strains.
25
  
2.4 Differences between Rotarix® and RotaTeq® 
 RotaTeq ® (RV1) Rotarix ® (RV5) 
Manufacturer Merck GlaxoSmith Kline Biologicals 
Conception Live, oral pentavalent Human, live attenuated 
Antigenic Composition 
G1, G2, G3, G4, P1A ressortant 
strains from bovine strain WC3 
(type G6P7[5]) 
G1P1A[8] from the human strain 
89-12 
Number of Doses 3 2 
Schedule 
2, 4, and 6 months 
(first dose should be given within 
2 and 4 months 
(first dose should be given within 
6-15 weeks of age and the last 
dose by 8 months of age, with at 
least 4 weeks in between doses) 
6-15 weeks of age and the last 
dose by 8 months of age, with at 
least 4 weeks in between doses) 
 Adapted from Lopman, et al., 2012.  
2.5 Rotavirus Vaccine Efficacy 
  Introduction of the rotavirus vaccines has been associated with reductions in 
gastroenteritis mortality.
7
 Substantial reductions in rotavirus hospitalizations in middle and high-
income countries have been observed as well. In high-income countries, including the US, 
Australia, Austria, Spain, and Israel, vaccine effectiveness was >85%, similar to that of clinical 
trials.
10, 26-29
 In upper middle-income Latin American countries, such as Mexico and Brazil, 
vaccine effectiveness varied from 79 to 94%.
30-32
 Effectiveness in El Salvador, a low middle-
income country, was 76%, not much different than the effectiveness in higher middle-income 
countries.
33 
  In developing countries in Africa and Asia, the efficacy of RotaTeq® and Rotarix® 
ranges from 39-77%. Though the efficacy of rotavirus vaccines is lower in developing countries 
than developed ones, the indirect vaccine benefits, such as herd immunity, are especially 
important in developing countries. These indirect benefits help to reduce transmission of 
rotavirus within the community. After the introduction of the rotavirus vaccines in low-middle 
and middle income Latin American countries, deaths and hospitalizations due to rotavirus 
decreased.
3
 Specifically, clinical trials in the high-mortality, low–income countries of South 
Africa and Malawi found a significant decrease in severe diarrheal episodes due to rotavirus after 
the introduction of the vaccine. 
2
 This suggests that similar reductions will take place in other 
high-mortality, low-income countries.  
  Wang and colleagues assessed the effectiveness of RotaTeq® following partial 
completion of the 3-dose regimen. One dose of RotaTeq® was associated with being 88% 
effective against preventing rotavirus gastroenteritis hospitalizations and ED visits and 44% 
effective against preventing all gastroenteritis hospitalizations and ED visits. Two doses of the 
vaccine were associated with 94% effectiveness in preventing rotavirus gastroenteritis 
hospitalizations and ED visits and 40% in preventing all gastroenteritis hospitalizations and ED 
visits. This illustrates that RotaTeq ® is effective against rotavirus even before a full vaccine 
regimen in complete.
4
 Likewise, another study found that RotaTeq® begins to protect children 
against hospitalizations and ED visits for rotavirus gastroenteritis as early as 14 days after the 
first dose and between doses as well.
5
  
  Few rotavirus vaccine efficacy studies have addressed both RotaTeq® and Rotarix® or a 
mixed vaccine regimen.  
2.6 Vesikari Scale 
   The Vesikari scale was developed in 1990 to assess diarrheal disease severity. It 
measures the duration of diarrhea, the maximum number of stools in a 24 hour period, the 
duration of vomiting, the maximum number of vomiting episodes in a day, temperature, 
dehydration, and treatment. The Vesikari scale is a widely accepted 20-point scale, in which a 
score of 1-10 indicates non-severe disease, and a score of 11 or above indicates severe disease.
12
 
It has been used to assess disease severity in vaccine efficacy studies of both RotaTeq® and 
Rotarix® in the US, Latin American, African, Middle Eastern, Asian, and European 
countries.
13,21-22
 
 
  
CHAPTER III: 
METHODOLOGY 
 
3.1 Study Design 
 The methodology of this case-control study has been described elsewhere.
11
 Briefly, active 
acute gastroenteritis (AGE) surveillance was conducted from January through June of 2010 and 
for the same period during 2011 in the Emergency Departments (ED) and inpatient floors at the 
three Children’s Healthcare of Atlanta (CHOA) hospitals. Parents of children who presented 
with a complaint of diarrhea were approached for enrollment. Patients were eligible for 
enrollment if they were: (1) diagnosed with acute gastroenteritis (AGE) defined as ≥ 3 looser 
than normal stools within a 24-hour period and diarrhea < 10 days at time of enrollment; (2) 
managed as an ED  patient, short-stay patient, or inpatient; (3) had no immunocompromising 
condition (e.g. malignancy, HIV infection); (4) had a stool sample collected from the patient 
within 14 days of presentation of illness with results available from a rotavirus antigen 
immunoassay; (5) eligible to have received at least 1 RV dose >14 days before presentation 
according to birth date (6) born on or after March 1, 2009 and age at evaluation >56days; and (7) 
lived in the usual catchment area of the hospital.  
Rotavirus testing on stool specimens was conducted at the Centers for Disease Control 
and Prevention (CDC) using commercial enzyme immunoassay (EIA) kit (Rotaclone) to 
determine whether patients were rotavirus positive (cases) or rotavirus negative (controls).  
This study was approved by institutional review boards of Morehouse School of 
Medicine, CDC and CHOA.  
 
3.2 Study Measures 
 Severity of disease was determined using the Vesikari scale. The Vesikari scale measures 
duration of diarrhea, maximum number of diarrheal episodes in a 24 hour period, duration of 
vomiting, maximum number of vomiting episodes in a 24 hour period, temperature, dehydration, 
and treatment. The Vesikari scale is a 20-point scale in which a score of >11 is considered 
severe. A score of 1-10 on the Vesikari scale is considered not severe. Patients were, therefore, 
classified as having severe or non-severe disease.
12-14
 Severe and non-severe patients were 
further categorized based on whether they received Rotarix®, RotaTeq®, or a mixed vaccine 
regimen and how many doses of rotavirus vaccine they received. Vaccine information was 
obtained from the state immunization registry and provider records. 
3.3 Study Definitions 
Vaccine Type 
 Participants were grouped into vaccine type cohorts based on their vaccine history at the 
time of illness, which was obtained from provider records and the state immunization registry. 
Participants categorized as RotaTeq® or Rotarix® only received that respective vaccine, 
regardless of the number of doses received. Receiving a mixed vaccine dose was defined as 
receiving at least one dose of RotaTeq® and at least one dose of Rotarix®.  
Race 
 Race was reported by the study participants’ guardian. The other race category included 
Asian, American Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or unknown.  
Insurance Status 
 Public insurance included Medicaid programs. Private insurance included PPO, HMO, 
and POS programs.   
 3.4 Statistical Analyses 
 The rotavirus positive and negative cohorts were established based on laboratory testing of 
stool samples. Odds ratios and a corresponding 95% CI for the relationship between disease 
status, vaccine type, number of doses of vaccine received, race, and insurance status and disease 
severity were calculated for each vaccine group. Similar analyses were conducted based on the 
number of doses of vaccine received. Univariate regression analysis of disease severity by 
disease status, vaccine type, number of vaccine doses, race, and insurance status were conducted. 
Multivariate regression analysis between disease severity and vaccine type while controlling for 
number of vaccine doses and demographic covariates were conducted as well.   
All analyses were conducted using a statistical software package (SPSS 19.0 version for 
Windows; SPSS Inc., Chicago, IL, USA).  
 
  
CHAPTER IV: 
RESULTS 
 
4.1 Descriptive Statistics 
 In two separate rotavirus seasons (January-June 2010 and 2011), 660 children who 
presented with AGE symptoms to one of the three CHOA hospitals' ED or inpatient departments 
were approached for enrollment into the study. One hundred and eleven guardians of approached 
patients declined participation. Reasons for refusal included not wanting to participate in 
research and not wanting to collect stool. Of the 549 children who consented to be in the study, 
stool samples were collected from 430 of them, and the remaining 119 patients were lost to 
follow up. Three of the subjects had to be withdrawn from the study. One subject was less than 
55 days old. A stool sample was collected more than 14 days after enrollment for another 
subject. The third subject was a duplicate enrollment. The remaining 427 stool samples were 
tested for rotavirus, and 119 were found to be rotavirus positive, whereas the other 308 were 
negative (Figure 1). 
More than half of all study participants, 273 (63.9%) had severe disease. In each vaccine 
type category, majority of participants had severe disease. Ninety-five (77.2%) children who did 
not receive, 48 (64.0%) children who received RotaTeq®, 73 (56.5%) children who received 
Rotarix®, 33 (55.9%) children who received mixed vaccine regimens, and 24 (60.0%) children 
who received at least one dose of an unknown vaccine type all developed severe disease. 
Similarly, 29 (65.9%) children who received only 1 vaccine dose, 103 (65.9%) children who 
received 2 doses, and 46 (52.3%) children who received 3 doses of rotavirus vaccine all 
developed severe disease (Table 2).  
119 (27.9%) participants were rotavirus positive and 308 (72.1%) were rotavirus 
negative. The largest vaccine group was Rotarix®, 130 (30.4%), followed by no vaccine, 123 
(28.8%), RotaTeq®, 75 (17.6%), and mixed dosing, 59 (13.8%). 40 (9.4%) participants received 
at least one unknown type of rotavirus vaccine. Study participants were most likely to receive 2 
doses of vaccine 172 (40.3%) or no vaccine 123 (28.8%). Majority of participants were Black, 
265 (62.1%) and had public insurance (multiple programs), 330 (72.2%) (Table 1). 
There was a significant difference in the likelihood of racial groups to be vaccinated 
(receive at least one dose of a rotavirus vaccine) (p-value: 0.001). Specifically, Hispanic children 
were more likely to be vaccinated than White children (OR 2.7, 95% CI: 1.1-6.7). There was no 
significant difference in the likelihood of Black children to be vaccinated when compared to 
White children (OR 0.7, 95% CI: 0.4-1.3). No significant differences were observed in the 
likelihood of children with public and private insurance to be vaccinated (p-value: 0.251).  
4.2 Univariate Analyses 
  Rotavirus positive children were more likely to have severe disease than rotavirus 
negative children (OR 3.8, 95% CI: 2.2-6.5). Receiving a mixed vaccine regimen had similar 
protection against severe disease to receiving only RotaTeq® or Rotarix® (Mixed: OR 0.4, 95% 
CI: 0.2-0.7; RotaTeq®: OR 0.5, 95% CI: 0.3-0.90; Rotarix®: OR 0.4, 95% CI: 0.2-0.7).  
Receiving one or two doses of vaccine, regardless of type, was protective against severe disease, 
when compared to children who did not receive vaccine (2 doses: OR 0.6, 95% CI: 0.3-0.9; 3 
doses: OR 0.4, 95% CI: 0.2-0.7). Black and Hispanic children were less likely to develop severe 
disease than White children (Black: OR 0.4, 95% CI 0.2-0.9; Hispanic: OR 0.3, 95% CI: 0.1-
0.7). Children with private insurance were also more likely to develop severe disease than those 
without insurance (OR 3.1, 95% CI 1.2-8.3) (Table 3).    
4.3 Multivariate Analyses 
 When controlling for number of doses and demographic covariates, receiving only 
RotaTeq® (n=75), only Rotarix® (n=130), or a combination of the two vaccines (n=59) all 
provided significant protection against severe disease when compared to children who did not 
receive vaccine (Mixed: OR 0.1, 95% CI: 0.02-0.5; RotaTeq®: OR 0.1, 95% CI: 0.02-0.5; 
Rotarix®: OR 0.1; 95% CI 0.01-0.3).  When controlling for vaccine type and other demographic 
covariates, only three doses of vaccine offered significant protection against severe disease (OR 
0.3, 95% CI: 0.2-0.6). In the multivariate model, Black and Hispanic children persisted in being 
less likely to develop severe disease than White children (Black: OR 0.4, 95% CI 0.2-0.8; 
Hispanic: OR 0.3, 95% CI 0.1-0.7). Children with private insurance were 4.0 times more likely 
to develop severe disease than those with no insurance (95% CI 1.2-12.9) (Table 4).   
 
  
CHAPTER V: 
DISCUSSION AND CONCLUSION 
 
5.1 Discussion  
The results of this study of children under three seen in an urban hospital system for 
diarrhea suggest children who receive a mix of both RotaTeq® and Rotarix® are adequately 
protected against severe disease, compared to children who do not receive vaccines. That is, 
children who receive mixed rotavirus vaccine regimens fare similarly to those who only receive 
RotaTeq® or Rotarix® in terms of protection against severe disease.  
Our analysis also revealed that children with private insurance were more likely to 
develop severe disease than children with no insurance. These findings contradict previous 
studies which found that the Medicaid population had a disproportionate number of 
hospitalizations from rotavirus gastroenteritis than other populations.
17-18
 Our contradictory 
findings may be attributed to children with private insurance already seeking medical attention 
elsewhere before coming to the ED, causing them to be enrolled in the study when their disease 
had progressed further.  
Despite well established racial and insurance-related disparities in rotavirus vaccination 
and disease, the disparities found in our studies are not consistent with those found in previous 
literature.
15-18
 We found that Black and Hispanic children were actually less likely to develop 
severe disease than White children. Yen and colleagues also found that White children were 
more likely to develop rotavirus gastroenteritis prior to the introduction of the rotavirus vaccines 
but had largely diminished in 2008.
15
 Whereas Yen and colleagues' study analyzed national data, 
the data set used for this study only evaluated children in the metro-Atlanta area. The national 
demographic profile differs from that of the metro-Atlanta area, which could account for 
different results. It is possible that although racial differences in rotavirus vaccination and 
disease have been largely diminished nationally, they may persist in localized areas.  
 A previous study of a five year period showed that several children may be excluded 
from receiving the rotavirus vaccine because they miss the age windows to receive doses.
20
 Our 
findings suggest that availability of a specific rotavirus vaccine should not be a factor in 
children’s failure to receive the rotavirus vaccine. Pediatricians should work to ensure that their 
patients receive a rotavirus vaccine on the proper schedule. Specifically, a child should receive a 
rotavirus vaccine on the proper schedule, even if the vaccine available at the time is not the same 
brand as the one they received previously.  
5.2 Limitations of the Study 
 This study had several limitations. Disease severity was determined using the Vesikari 
scale. The Vesikari scale is dichotomous and categorizes diarrheal disease as severe or non-
severe, which does not give a full understanding of the range of disease severity among study 
participants. Other scales of diarrheal disease severity categorize disease into more than two 
categories. These scales also consider factors not included in the Vesikari scale, such as 
behavioral signs and symptoms, to determine disease severity.
19 
5.3 Recommendations 
 In the future, it may be helpful to assess disease severity using a different scale. The sample size 
used for our analysis was relatively small. More studies should be conducted to further evaluate 
the efficacy of mixed rotavirus vaccine regimens. 
 
 
5.4 Conclusion  
 Three doses of rotavirus vaccine, regardless of vaccine type, are protective against severe 
disease, but one or two doses are not. Receiving a mixed regimen of vaccine is also effective in 
preventing severe disease. As such, pediatricians should give patients the rotavirus vaccine on 
schedule, regardless of the type of vaccine. They should also continue to stress the importance of 
receiving all doses of the rotavirus vaccine. More studies should be done to evaluate the impact 
and effectiveness of mixed rotavirus vaccine regimens.  
  
Figure 1. Diagram of all patients approached and enrolled in study. 
 
 
From the 430 patients who stool samples were collected from, 3 were withdrawn from the 
dataset. (One patient was younger than 55 days, one stool sample was collected more than 14 
days after enrollment, and one patient had previously been enrolled in the study). Majority of the 
patients who declined participation did so because they did not want to participate in research or 
did not want to collect stool.  
  
660 
Approached for enrollment 
 
111 
Declined participation 
549  
Enrolled 
430 
Stool samples collected 
 
3 
Withdrawn 
119 
Rotavirus Positive 
308 
Rotavirus Negative 
Table 1. Descriptive statistics of enrolled subjects (n = 427).  
 
Variables 
All Rotavirus 
Positive 
(n=119) 
Rotavirus 
Negative 
(n=308) Sample 
 
p-value 
Severity     
Not severe 154 (36.1%) <0.0001 20 (16.8%) 134 (43.5%) 
Severe 273 (63.9%)  99 (83.2%) 174 (56.5%) 
Vaccine Type     
RotaTeq  ® 75 (17.6%) 0.0047 15 (12.6%) 60 (19.5%) 
Rotatirx ® 130 (30.4%)  23 (19.3%) 107 (34.7%) 
Mixed dose 59 (13.8%)  8 (6.7%) 51 (16.6%) 
None 123 (28.8%)  65 (55.5%) 58 (18.8%) 
Unknown 40 (9.4%)  8 (6.7%) 32 (10.4%) 
Vaccine Dose     
0 doses  123 (28.8%) 0.0090 65 (54.6%) 58 (18.8%) 
1 dose 44 (10.3%)  10 (8.4%) 34 (11.0%) 
2 doses 172 (40.3%)  31 (26.1%) 128 (45.8%) 
3 doses 88 (20.6%)  13 (10.9%) 75 (24.4%) 
Gender     
Male 244 (57.1%) 0.4153 63 (52.9%) 181 (58.8%) 
Female 183 (42.9%)  56 (47.1%) 127 (41.2%) 
Age:      
0-2 months 21 (4.9%) 0.2943 5 (4.2%) 16 (5.2%) 
3-5 months 75 (17.6%)  12 (10.1%) 63 (20.5%) 
6-8 months 91 (21.3%)  19 (16%) 72 (23.4%) 
9-11 months 78 (18.3%)  17 (14.3%) 61 (19.8%) 
12-23 months 155 (36.3%)  61 (51.3%) 94 (30.5%) 
> 24 months 7 (1.6%)  5 (4.2%) 2 (0.6%) 
Race     
White 59 (13.8%) 0.0266 16 (13.4%) 43 (14%) 
Black 265 (62.1%)  81 (68.1%) 184 (59.7%) 
Hispanic 80 (18.7%)  14 (11.8%) 66 (21.4%) 
Other 23 (5.4%)  8 (6.7%) 15 (4.9%) 
Insurance     
Public 330 (72.2%) 0.0206 86 (72.3%) 244 (79.2%) 
Private 31 (7.3%)  11 (9.2%) 20 (6.5%) 
None 50 (11.7%)  16 (13.4%) 34 (11%) 
Unknown 16 (3.7%)  6 (5%) 10 (3.2%) 
 
Disease severity was defined using the Vesikari scale. Participants who received a mixed vaccine 
dose were defined as those who received at least one dose of RotaTeq® and one dose of 
Rotarix®. The vaccine dose category represents the number of rotavirus vaccines a patient had 
received at the time of their illness, regardless of the number of doses received. The other race 
category included Asian, American Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or 
unknown. Private insurance included PPO and HMO. Public insurance refers to Medicaid 
programs.   
Table 2. Percentage of vaccine type and dose among subjects with severe disease (n=273).  
 Severe Disease p-value 
Vaccine Type   
  None 95 (77.2%) 
0.005 
  RotaTeq  ®  48 (64.0%) 
Rotarix  ® 73 (56.5%) 
Mixed 33 (55.9%) 
Unknown 24 (60.0%) 
Vaccine Doses   
   0 doses 95 (77.2%) 
0.001 
 1 dose 29 (65.9%) 
 2 doses 103 (60.0%) 
  3  doses 46 (52.3%) 
 
Disease severity was defined using the Vesikari scale. Participants who received a mixed vaccine 
dose were defined as those who received at least one dose of RotaTeq® and one dose of 
Rotarix®. The vaccine dose category represents the number of rotavirus vaccines a patient had 
received at the time of their illness, regardless of the number of doses received.   
Table 3. Univariate analysis of disease severity by covariates. 
 
 
Variables Severe Disease 
 OR 95% CI p-value 
Disease Status    
Rotavirus Negative 1.00 Referent  
  Rotavirus Positive 3.8 2.2-6.4 <0.001 
Vaccine Type    
  None 1.00 Referent  
  RotaTeq  ®  0.5 0.4-0.9 0.036 
Rotarix  ® 0.4 0.2-0.7 <0.001 
Mixed 0.4 0.2-0.7 0.003 
Vaccine Doses    
   0 doses 1.00 Referent  
 1 dose 0.6 0.3-1.3 0.216 
 2 doses 0.6 0.3-0.9 0.024 
  3  doses 0.4 0.2-0.7 0.001 
Race    
  White 1.00 Referent  
 Black 0.4 0.2-0.9 0.017 
 Hispanic 0.3 0.1-0.7 0.003 
  Other 0.5 0.1-1.4 0.176 
Insurance    
None 1.00 Referent  
Public 0.7 0.4-1.3 0.0074 
Private 3.1 1.2-8.3 0.0856 
Unknown 2.6 0.7-9.2 0.3022 
 
Disease severity was defined using the Vesikari scale. Participants who received a mixed vaccine 
dose were defined as those who received at least one dose of RotaTeq® and one dose of 
Rotarix®. There were 40 (9.4%) patients who received at least one rotavirus vaccine of an 
unknown type and were, therefore, not included in the analysis.  The vaccine dose category 
represents the number of rotavirus vaccines a patient had received at the time of their illness, 
regardless of the number of doses received. The other race category included Asian, American 
Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or unknown. Private insurance 
included PPO and HMO. Public insurance refers to Medicaid programs.   
Table 4. Multivariate analysis of disease severity by covariates. 
 
 
Variables Severe Disease 
 OR 95% CI p-value 
Vaccine Type    
  None 1.0 Referent  
  RotaTeq  ®  0.1 0.02-0.5 0.006 
Rotarix  ® 0.1 0.01-0.3 0.001 
Mixed 0.1 0.02-0.5 0.004 
Vaccine Doses    
   0 doses 1.00 Referent  
 1 dose 0.7 0.3-1.5 0.400 
 2 doses 0.7 0.4-1.1 0.135 
  3  doses 0.3 0.2-0.6 <0.001 
Gender    
Male 1.0 Referent  
Female 0.8 0.5-1.2 0.354 
Age    
0-2 months 1.0 Referent  
3-5 months 1.0 0.4-2.8 0.937 
6-8 months 1.4 0.5-3.8 0.491 
9-11 months 2.0 0.7-5.6 0.168 
12-23 months 1.7 0.7-4.5 0.254 
24+ months 1.7 0.3-12.0 0.571 
Race    
  White 1.0 Referent  
 Black 0.4 0.2-0.8 0.014 
 Hispanic 0.3 0.1-0.7 0.006 
  Other 0.3 0.1-1.1 0.063 
Insurance    
None 1.0 Referent  
Public 1.6 0.9-3.1 0.128 
Private 4.0 1.2-12.9 0.021 
Unknown 3.5 0.9-14.5 0.083 
 
Disease severity was defined using the Vesikari scale. Participants who received a mixed vaccine 
dose were defined as those who received at least one dose of RotaTeq® and one dose of 
Rotarix®. There were 40 (9.4%) patients who received at least one rotavirus vaccine of an 
unknown type and were, therefore, not included in the analysis. The vaccine dose category 
represents the number of rotavirus vaccines a patient had received at the time of their illness, 
regardless of the number of doses received. The other race category included Asian, American 
Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or unknown. Private insurance 
included PPO and HMO. Public insurance refers to Medicaid programs.  
  
REFERENCES 
1. Bernstein DI. Rotavirus overview. Pediatric Infectious Disease Journal; 2009: 28(3): 
S50-S53.  
2. World Health Organization. Rotavirus. 2011.  
3. Patel MM, Steele D, Gentsch JR, et al Real-world impact of rotavirus vaccination. 
Pediatric Infectious Disease Journal; 2011, 30: S1-S5.  
4. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of an incomplete RotaTeq ® (RV5) 
vaccination regimen in preventing rotavirus gastroenteritis in the United States. Pediatric 
Infectious Disease Journal; 2012.  
5. Dennehy PH, Vesikari T, Matson DO. Efficacy of the pentavalent rotavirus vaccine, 
RotaTeq ® (RV5), between doses of a 3-dose series and with less than 3 doses 
(incomplete regimen). Human Vaccines; 2011, 7(5): 563-568.  
6. Goldman RD. Effectiveness of rotavirus vaccine in preventing severe acute 
gastroenteritis in children. Canadian Family Physician; 2012, 58: 270-271.  
7. Lopman BA, Payne DC, Tate JE, et al. Post-licensure experiences with rotavirus 
vaccination in high and middle income countries; 2006 to 2011. Current Opinion in 
Virology; 2012, 2: 434-442.  
8. Dore DD, Turnbull BR, Seeger JD. Vaccine discontinuation and switching following 
regulatory interventions in response to rotavirus vaccine contamination porcine circovirus 
DNA fragments. Pharmacoepidemiology and Drug Safety, 2012; 21: 415-419. 
9. Jiang V, Jiang B, Tate J, et al. Performance of rotavirus vaccines in developed and 
developing countries. Human Vaccination, 2010; 6(7): 532-542. 
10. Castilla J, Beristain X, Martinez-Artola, V., et al. Effectiveness of rotavirus vaccines in 
preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. 
Vaccine; 2012, 30: 539-543. 
11. Cortese MM, LeBlanc J, White KE, et al. Leveraging state immunization information 
systems to measure effectiveness of rotavirus vaccination. Pediatrics; 2011, 128: 1474-
1481.  
12. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for 
clinical severity of diarrhoel episodes. Scandinavian Journal of Infectious Diseases; 
1990, 22(3): 259-267.  
13. Perez-Schael I, Salinas B, Tomat M, et al. Efficacy of the human rotavirus vaccine 
RIX4414 in malnourished children. Journal of Infectious Diseases; 2007; 196: 537-540. 
14. Salinas B, Perez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and 
efficacy of an attenuated rotavirus vaccine RIX4414: a randomized, placebo-controlled 
trial in Latin American infants. Pediatric Infectious Disease Journal; 2005, 24(9): 807-
816.  
15. Yen C, Steiner CA, Barrett M, et al. Racial disparities in diarrhea-associated 
hospitalizations among children in five US states, before and after introduction of 
rotavirus vaccine. Vaccine; 2010, 28: 7423-7426.  
16. Fischer TK, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and 
rotavirus among children <5 years of age in the United States, 1993-2003. Journal of 
Infectious Diseases; 2007, 195: 1117-1125.  
17. Pont SJ, Grijalva CG, Griffin MR, et al. National rates of diarrhea-associated ambulatory 
visits in children. Journal of Pediatrics; 2009, 155: 56-61.  
18. Ma L, El Khoury AC, Itzler RF. The burden of rotavirus hospitalizations among 
Medicaid and non-medicaid children younger than 5 years old. American Journal of 
Public Health; 2009, 99: S398-S404.  
19.  Givon-Lavi N, Greenberg D, Dagan R. Comparison between two severity scoring scales 
commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine; 2008, 
26: 5798-5801.  
20. Tate JE, Steele AD, et al. Research priorities regarding rotavirus vaccine and 
intussusception: A meeting summary. Vaccine; 2012, 30: A179-A184. 
21. Vesikari T, Karvonen A, et al. Efficacy of human rotavirus vaccine against rotavirus 
gastroenteritis during the first 2 years of life in European infants: randomised, double-
blind controlled study. The Lancet; 2007, 370(9601): 1757-1763.  
22. Khoury H, Ogilvie I, et al. “Burden of rotavirus gastroenteritis in the Middle Eastern and 
North African pediatric population. BMC Infectious Diseases; 2011, 11(1): 9.  
23. Wang FT, Mast TC, et al. Effectiveness of the pentavalent rotavirus vaccine in preventing 
gastroenteritis in the United States. Pediatrics; 2010, 125(3): 208-213.  
24. Rheingans RD, et al. Economic costs of rotavirus gastroenteritis and cost-effectiveness of 
vaccination in developing countries. Journal of Infectious Diseases; 2009, 200: S16-S27.  
25. McClenahan SD, Krause PR, Uhlenhaut C. Molecular and infectivity studies of porcine 
circovirus in vaccines. Vaccine; 2011, 29(29-30): 4745-4753.  
26. Paulke-Korinek M, Rendi-Wagner, et al. Universal mass vaccination against rotavirus 
gastroenteritis: impact on hospitalization rates in Austrian children. Pediatric Infectious 
Disease Journal; 2010, 29: 319-323.  
27. Muhsen K, Chodick G, et al. The uptake of rotavirus vaccine and its effectiveness in 
preventing acute gastroenteritis in the community. Vaccine; 2010, 29: 91-94. 
28. Staat MA, Payne DC, et al. Effectiveness of pentavalent rotavirus vaccine against severe 
disease. Pediatrics; 2011, 128: 267-275. 
29. Buttery JP, Lambert SB, et al. Reduction in rotavirus-associated gastroenteritis following 
introduction of rotavirus vaccine into Australia’s National Childhood vaccine schedule. 
Pediatric Infectious Disease Journal; 2011, 30: S25-S29.  
30. Justino MC, Linhares AC, et al. Effectiveness of the monovalent G1P[8] human rotavirus 
vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belem, 
Brazil. Pediatric Infectious Disease Journal; 2011, 30: 396-401. 
31. Correia JB, Patel MM, et al. Effectiveness of monovalent rotavirus (Rotarix) against 
severe diarrhea caused by serotypically unrelated G2P[4}] strains in Brazil. Journal of 
Infectious Diseases; 2011, 30: 396-401.  
32. Yen C, Figueroa JR, et al. Monovalent rotavirus vaccine provides protection against 
emerging fully heterotypic G9P[4] rotavirus strain in Mexico. Journal of Infectious 
Diseases 2011, 204: 783-786.  
33. Gurgel RQ, Correia JB, Cuevas LE. Effect of rotavirus vaccination on circulating virus 
strains. The Lancet; 2008, 371: 301-302.  
 
 
   
 
 
 
